Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carl Icahn Pitches Nominees for Biogen Idec Board

This article was originally published in The Pink Sheet Daily

Executive Summary

In a letter to shareholders, billionaire investor says his slate of candidates would consider a credible bid for the company.

You may also be interested in...



But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”

After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board

But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”

After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board

Icahn Wins Two Seats On Biogen Idec’s Board

Icahn Partners’ Managing Director Alex Denner claims victory after a drama-packed day that took an unusual twist.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel